US imaging firms protest over proposed CTA cover
This article was originally published in Clinica
Executive Summary
A proposal by the US Centers for Medicare and Medicaid Services (CMS) to impose tight Medicare coverage conditions on the ever-growing practice of computed tomographic angiography (CTA) has met with a wave of protest from cardiologists, radiologists and industry. The CMS is due to issue its final ruling in the next few days.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.